Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Moxifloxacin hydrochloride
Drug ID BADD_D01502
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status approved; investigational
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D00874
MeSH ID D000077266
PubChem ID 101526
TTD Drug ID D0ZV0Z
NDC Product Code 48943-0025; 55111-064; 58032-0131; 40032-034; 60429-893; 50370-0001; 51927-4833; 51991-943; 72789-037; 29967-0005; 49574-522; 63323-850; 65862-627; 0093-7387; 50090-4100; 70518-3738; 51927-0167; 0781-7135; 49587-106; 50090-4058; 66298-8507; 67296-1616; 67457-323; 72789-038; 13668-201; 0078-0939; 65862-603; 68084-722; 0832-1410; 50268-576; 51927-0089; 57237-156
UNII C53598599T
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H25ClFN3O4
CAS Registry Number 186826-86-8
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oral infection11.01.04.005; 07.05.07.005--Not Available
Hypoacusis04.02.01.006--
Red blood cell sedimentation rate increased13.01.03.001--Not Available
Tachyarrhythmia02.03.02.008--Not Available
Blood bilirubin decreased13.03.04.017--Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Platelet count increased13.01.04.002--Not Available
Eye pruritus06.04.05.006--Not Available
Ocular discomfort06.08.03.008--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling08.02.03.017; 12.07.03.018--Not Available
Affect lability19.04.01.001--Not Available
Transaminases increased13.03.04.036--Not Available
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Haemorrhage24.07.01.002--Not Available
Fluid intake reduced14.05.10.001--Not Available
Vulvovaginal pruritus21.08.02.004; 23.03.12.009--Not Available
Vasodilation procedure25.03.01.001--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Gastric pH decreased13.05.04.001--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Calcium ionised increased13.11.01.018--Not Available
Allergic oedema08.01.07.014; 10.01.03.025--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages